Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early Amyloid Formation and Neuroinflammatory Response in a Bigenic Mouse Model Expressing Human α-Synuclein and Aβ.

Parkinson's disease·2026

Same author

Aβ antibodies target not only amyloid plaques but also distinct brain cells and vessels.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Same author

One of the binding proteins for administered amyloid-β appears to be anti-Aβ IgG antibody in amyloid plaques.

Journal of Alzheimer's disease : JAD·2025

Same author

Neuronal endolysosomal alterations induced by Apolipoprotein E4 emerge over time in primary neurons.

The Journal of biological chemistry·2025

Same author

Microglia degrade Alzheimer's amyloid-beta deposits extracellularly via digestive exophagy.

Cell reports·2024

Same author

Correction: Apolipoprotein E intersects with amyloid-β within neurons.

Life science alliance·2024

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Immunotherapy for Alzheimer disease.

Gunnar K Gouras¹

¹Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY 10065, USA. gkgouras@med.cornell.edu

|January 12, 2010

Summary

Immunotherapy targeting beta-amyloid is a leading Alzheimer disease treatment. Research shows it reduces brain plaques and improves behavior in mouse models, with clinical trials underway.

Area of Science:

Neuroscience
Immunology
Pharmacology

Background:

Alzheimer disease is a progressive neurodegenerative disorder characterized by amyloid plaque accumulation.
Current therapeutic strategies focus on targeting beta-amyloid peptides.
Immunotherapy represents a promising avenue for Alzheimer disease treatment.

Purpose of the Study:

To review the current landscape of immunotherapy for Alzheimer disease.
To discuss the efficacy of active and passive immunotherapies targeting beta-amyloid.
To highlight ongoing challenges and future directions in Alzheimer disease immunotherapy.

Main Methods:

Review of preclinical studies using transgenic mouse models.
Analysis of clinical trial data for immunotherapy interventions.

More Related Videos

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Discussion of immunological mechanisms underlying therapeutic effects.

Main Results:

Immunotherapy targeting beta-amyloid has demonstrated significant reduction in plaque pathology in animal models.
Behavioral improvements have been observed in transgenic mice treated with immunotherapy.
Several immunotherapy clinical trials for Alzheimer disease are currently in progress.

Conclusions:

Immunotherapy targeting beta-amyloid is a key therapeutic strategy for Alzheimer disease.
Further research and clinical trials are essential to overcome challenges and optimize treatment efficacy.
Immunological approaches hold significant potential for managing Alzheimer disease progression.